Table 4.
Univariate and Multivariate Analysis for PFS and OS
| Variables | PFS | OS | ||||||
|---|---|---|---|---|---|---|---|---|
| 3-Year Rate, % | p value (Univariate) | Hazard Ratio (95% CI) | p value (Multivariate) | 3-Year Rate, % | p value (Univariate) | Hazard Ratio (95% CI) | p value (Multivariate) | |
| Age (years) | 0.044 | 0.125 | 0.611 | |||||
| <50 | 22.7 | 72.7 | ||||||
| ≥50 | 46.8 | 77.9 | ||||||
| T stage | 0.130 | 0.296 | ||||||
| 1 | 30.0 | 70.0 | ||||||
| 2–3 | 46.4 | 79.7 | ||||||
| pN stage | 0.002 | <0.001 | 0.033 | 0.143 | ||||
| 0–2 | 50.7 | 1 | 82.2 | |||||
| 3 | 15.4 | 2.872 (1.676–4.921) | 61.5 | |||||
| Breast surgery | 0.971 | 0.064 | ||||||
| Mastectomy | 42.0 | 79.5 | ||||||
| BCS | 36.4 | 54.5 | ||||||
| Histologic grade | 0.649 | 0.308 | ||||||
| 2 | 39.2 | 72.5 | ||||||
| 3 | 43.7 | 81.2 | ||||||
| Molecular subtype | 0.776 | 0.860 | ||||||
| Luminal | 38.5 | 74.4 | ||||||
| HER2-enriched | 40.0 | 76.7 | ||||||
| Triple-negative | 46.7 | 80.0 | ||||||
| HR | 0.228 | 0.421 | ||||||
| Positive | 35.8 | 73.6 | ||||||
| Negative | 47.8 | 80.4 | ||||||
| HER-2 | 0.851 | 0.987 | ||||||
| Positive | 40.0 | 76.7 | ||||||
| Negative | 42.0 | 76.8 | ||||||
| Adjuvant radiotherapy | 0.871 | 0.280 | ||||||
| Yes | 40.5 | 71.4 | ||||||
| No | 42.1 | 80.7 | ||||||
| Therapy strategy | 0.048 | 0.002 | 0.004 | 0.364 | ||||
| Systemic therapy | 30.2 | 1 | 62.8 | |||||
| Combined therapy | 50.0 | 0.429 (0.254–0.724) | 87.5 | |||||
| ISLM chemotherapy | 0.292 | 1.000 | ||||||
| Yes | 43.5 | 76.5 | ||||||
| No | 28.6 | 78.6 | ||||||
| ISLM hormonal therapy | 0.369 | 0.345 | ||||||
| Yes | 35.9 | 71.9 | ||||||
| No | 45.0 | 80.0 | ||||||
| ISLM radiotherapy | 0.003 | 0.191 | 0.001 | 0.002 | ||||
| Yes | 58.1 | 93.0 | 1 | |||||
| No | 28.6 | 64.3 | 6.700 (1.989–22.569) | |||||
| Neck surgery | 0.055 | 0.698 | ||||||
| Yes | 25.9 | 74.1 | ||||||
| No | 47.2 | 77.8 | ||||||
Abbreviations: PFS, progression-free survival; OS, overall survival; CI, confidence interval; T, tumor; LN, lymph node; BCS, breast-conserving surgery; HER2, human epidermal growth factor receptor 2; ISLM, ipsilateral supraclavicular lymph node metastasis; HR, hormone receptor.